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Abstract
Background: Developing a safe and effective vaccine will be the principal way of controlling the COVID-19
pandemic. However, current COVID-19 vaccination trials are not adequately representing a diverse participant
population in terms of age, ethnicity and comorbidities. Achieving the representative recruitment targets that are
adequately powered to the study remains one of the greatest challenges in clinical trial management. To ensure
accuracy and generalisability of the safety and efficacy conclusions generated by clinical trials, it is crucial to recruit
patient cohorts as representative as possible of the future target population. Missing these targets can lead to
reduced validity of the study results and can often slow down drug development leading to costly delays.
Objective: This study explores the key factors related to perceptions and participation in vaccination trials.
Methods: This study involved an anonymous cross-sectional online survey circulated across the UK. Statistical
analysis was done in six phases. Multi-nominal logistic models examined demographic and geographic factors that
may impact vaccine uptake.
Results: The survey had 4884 participants of which 9.44% were Black Asian Minority Ethnic (BAME). Overall, 2020
(41.4%) respondents were interested in participating in vaccine trials; 27.6% of the respondents were not interested
and 31.1% were unsure. The most interested groups were male (OR = 1.29), graduates (OR = 1.28), the 40–49 and
50–59 age groups (OR = 1.88 and OR = 1.46 respectively) and those with no health issues (OR = 1.06). The least
interested groups were BAME (OR = 0.43), those from villages and small towns (OR = 0.66 and 0.54 respectively) and
those aged 70 and above (OR = 1.11).
Conclusions: In order to have a vaccination that is generalisable to the entire population, greater work needs to be
done in engaging a diverse cohort of participants. Public health campaigns need to be targeted in improving trial
recruitment rates for the elderly, BAME community and the less educated rural population.
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Highlights
 This study investigated demographic factors in
COVID-19 vaccine trial participation.
 Our results show that only 41.4% are interested in
partaking in vaccination trials.
 Male graduates and with no health issues are most
interested in trial participation.
 Participation interest is lowest from rural and high-
risk groups (BAME and elderly).
 Recruitment challenges will remain as phase 3 trials
continue in 2021.
Background
COVID-19 is an infectious respiratory condition that is
caused by severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) [1]. It was initially detected in Wuhan
in November 2019 and has rapidly become a global pan-
demic. As of 1st April 2021, it has infected 129 million
people and caused 2.8 million deaths globally [2]. Evi-
dence has established that COVID-19 is mainly spread
via droplets and contact, with clinical characteristics of a
febrile and inflammatory biphasic illness with associated
respiratory tract inflammation [3, 4]. Of notable concern
is how asymptomatic people are playing a major role in
the transmission of this virus as it seems to shed at high
concentrations from the nasal cavity before symptom de-
velopment [5].
The first wave of the pandemic led to worldwide cur-
fews and social distancing restrictions to prevent the fur-
ther spread of COVID-19, with as many as 3.9 billion
people being in some form of lockdown in the first week
of April 2020. A second wave of lockdown measures was
re-introduced for most of Europe and Asia in October
and November 2020, placing a huge burden on the
economy and people’s mental and physical wellbeing [6].
Ultimately, developing a vaccine will be the principal
way of controlling this pandemic and curbing the
COVID-19 death toll. As of yet, there are currently no
licenced vaccines for COVID-19. Before a vaccine can
be manufactured, distributed and administered to the
population, it must first be deemed safe and effective [7].
Clinical trials are considered to be the most reliable and
traditional way of testing a new vaccine [8]. Reaching
the representative recruitment targets that are ad-
equately powered to the study remains one of the great-
est challenges in clinical trial management. Only
approximately 50% of vaccine clinical trials in the UK
achieve their recruitment target, resulting in approxi-
mately one third of trial terminations [9].
Thus, it is crucial to recruit a panel of patients as rep-
resentative as possible of the future target population.
This is to ensure the accuracy and generalisability of the
efficacy and safety conclusions generated by clinical
trials [10]. The vaccine trials should also represent a di-
verse participant population in terms of age, ethnicity
and comorbidities. Missing these targets can lead to a
reduced validity of the study results and can often slow
down drug development leading to costly delays [11].
This study explores the key factors related to percep-
tions and participation in vaccination trials. Understand-
ing the demographics of those who are less likely to
partake in trials will help to target strategies in recruiting
patients to trials.
Methods
Survey design and study population
This study was developed as a national anonymous
cross-sectional online survey to help inform service
decision-making. The survey was in English, hosted via
Google forms and was open from 4th September 2020
to 9th October 2020. The survey was circulated across
the UK through social media networks (Facebook, Twit-
ter, LinkedIn and Instagram), national radio, news arti-
cles, the National Institute for Health Research (NIHR)
Clinical Research Network West Midlands (CRN WM)
website and newsletter and through 150 general prac-
tices via a text messaging service. Particular focus was
put into targeting BAME groups through targeting
BAME-specific social media and media outlets.
The interview questions were externally reviewed by
the CRN WM Equality, Diversity and Inclusion Research
Champions Group. Feedback from this group led to
changes being made to the questions in order to make
them more easily understandable, prior to the survey go-
ing live.
The survey consisted of several sections. First, Likert
rating scales were used to determine the extent of agree-
ment regarding various statements about COVID-19 and
vaccinations. The survey then focused on previous vac-
cination habits (e.g. if the respondent had ever declined
vaccinations) and whether they would be interested in
taking part in the trial. The final section collected the re-
spondent’s demographics. Once they had completed the
survey, respondents were provided with a link to the
NIHR ‘Be Part of Research’ website, as to how they
could find out more about participating in the trials.
The full survey can be found in Additional file 1.
This study was approved by local approval processes
by the CRN WM. No ethical-related issues were identi-
fied. Participants were provided with information about
the study and how the data was going to be dissemi-
nated in the initial page of the survey. This was an en-
tirely anonymous survey with no identifiable material or
information collected. Specific or individual consent was
not obtained as the patients were participating without
providing any identifiable material.
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Statistical analysis
The statistical analysis was done in six phases. The first
described the data of the participants of the COVID-19
survey, including the various factors considered in the
analysis. In the second phase, a postcode analysis was
conducted to explore the regional variations in participa-
tion of the vaccine trials. Postcodes were classified into
six subgroups (i.e. core city, other cities, large town,
medium town, small town and village) based on the UK
government’s postcode classification for population dis-
tribution. ‘Core cities’ include 12 major population and
economic centres (London, Birmingham, Glasgow, Liv-
erpool, Bristol, Manchester, Sheffield, Leeds, Edinburgh,
Cardiff, Nottingham and Newcastle-upon-Tyne). The
other subgroups are based on settlement population:
‘other cities’ greater than 175,000, ‘large town’ between
60,000 and 174,999, ‘medium town’ between 25,000 and
59,999, ‘small town’ between 7500 and 24,999, and ‘vil-
lage’ below 7500 [12].
The third phase investigated the various factors influ-
encing the respondents’ interest in vaccination trials.
This analysis was done using a multinomial logistic re-
gression model to estimate odds ratio for these factors.
This included age, gender, ethnicity (BAME and non-
BAME), diagnosed health condition, smoking status and
qualification. The fourth phase examined those who
were ‘not-interested’ in trial participation group, espe-
cially focusing on the impact of ethnicity and age. In the
fifth phase, the differences in the mean scores of the
questionnaire were explored to examine how it varied
across participants who were interested in trials. Finally,
in the last phase, a principal component analysis was
used to explore the perception of vaccine and its effect
on participation in vaccine trials. All analysis was carried
out in STATA version 16.
Results
A total of 4884 respondents completed the survey. The
majority were females (n = 3416, 69.9%) and of White
ethnicity (n = 4127, 84.5%). There were 461 BAME re-
spondents (9.44%), amongst which 258 (5.3%) were
Asian/Asian British-Indian and 67 (1.38%) were Black/
African/Caribbean/Black British. The majority of the re-
spondents were qualified up to at least A-level (n = 1574,
32.2%), with 1780 (36.4%) university undergraduate de-
gree holders and 1010 (20.7%) post-graduate respon-
dents. The age group between 50 and 59 years was the
largest participant age group (1101 responses, 22.5%),
with 552 (11.3%) responses from those aged 70 and
above. 39.9% (n = 1949) of the respondents stated diag-
nosed health issues.
Overall, 2020 (41.4%) respondents were interested in
participating in vaccine trials. 27.6% (1348) of the re-
spondents were not interested in vaccine trials and
31.1% (1518) were unsure. See Table 1 for the full
breakdown.
The results presented in Table 2 shows that maximum
participation was from ‘other cities’ (29.07%) followed by
‘small town’ (22%). Of those respondents not interested
in participating in vaccine trials, the majority were from
‘villages’ (31.95%) whilst 46.18% (n = 701) of the respon-
dents who were unsure were from ‘small towns’. Table 3
shows that whilst the maximum number of male respon-
dents interested in trials were from ‘medium town’ (248,
35.6%), the majority of the interested females were from
‘other city’ (494, 37.5%). Whilst the majority of the grad-
uates and post-graduates who were interested in trials
were from ‘other city’, a significant number of non-
university goers who were interested in trials were from
‘medium town’. Respondents aged 50 and less who were
interested in vaccine trials lived in ‘other city” whilst
those aged 60 and over that were interested in trials
came from ‘medium town’.
Figure 1 presents the chart-view of the odds ratio
(OR) of the various factors that significantly influence
respondent’s interest in participating in COVID-19 vac-
cine trials. The results indicate that respondents from
‘village’ (OR = 0.66) and ‘small town’ are less likely to
participate in vaccine trials, as are non-graduates (OR =
0.85) and those of the BAME ethnicity (0.43). Further-
more, groups more likely to participate included males
(OR = 1.29), graduates (OR = 1.28) and the 40–49, 50–59
and 60–69 age groups (OR = 1.88, OR = 1.46 and OR =
1.12 respectively). The results also confirm that respon-
dents with no known health issues are more likely to
participate in vaccine trials (OR = 1.60). However, young
adults (aged 18–39) were less interested in participating
in the vaccine trials (OR = 0.57).
In total, 2864 respondents (58.64%) were classified as
‘non-participants’ in vaccine trials, which is defined as
those who were unsure or would choose not to partici-
pate in trials. Three hundred forty-six respondents
(27.60%) would choose not to participate in trials and
1518 (31.10%) respondents were unsure. In the ‘non-par-
ticipant’ group, females accounted for 73.25% (n = 2098),
whilst 39% (n = 1167) reported diagnosed health issues.
7.75% (n = 222) were smokers. Amongst the qualification
classifications, university graduates accounted for 36.35%
(n = 1041), followed by non-graduates (32.09%, n = 919).
Respondents without formal qualifications only consti-
tuted 2.55% (n = 73). Concerning the age groups, the
number of ‘non-participant’ respondents was highest in
the 40–49 (21.41%) and 50–59 (21.72%) age groups.
Only 11.33% (n = 315) of respondents in the ‘non-uptake’
group were in the age group 70 years and above. The
BAME community accounted for 7.23% (n = 158) whilst
86.45% (n = 818) belonged to the non-BAME commu-
nity. Of those who would choose not to participate in
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vaccine trials, 15.22% (n = 436) indicated that they have
previously declined vaccinations. The details are re-
ported in Tables 4 and 5. Tables 6 and 7 provide the de-
tails of the postcode analysis of the non-participant
group. ‘Core city’ and ‘small towns’ accounted for the
majority of these ‘non-participants’.
Table 5 reports the mean scores of respondents’ per-
ceptions of vaccines and their effect on participation in
vaccine trials. For the survey, a 5-point Likert scale was
used, i.e. strongly disagree (1), disagree (2), neutral (3),
agree (4) and strongly agree (5). The mean scores for all
the questions are above three. The scores are signifi-
cantly higher in all of the questions for those respon-
dents who are interested in vaccine trials. Furthermore,
it is evident that the standard deviation was very low for
this group as compared to those who were not interested
in trials (details are provided in Table 8). This indicates
that even though the respondents tend to agree on the
importance and necessity of COVID-19 vaccine trials,
the responses varied considerably. There was a signifi-
cant difference in the mean scores of the responses be-
tween the BAME and the non-BAME community. Mean
scores of the former were considerably higher than those
of the latter community, although standard deviations
were lower. The scores were also significantly different
across the postcode classifications. In particular, the
mean scores of ‘Medium Town’ were significantly higher
than the others for the questions related to vaccine tri-
als. The maximum number of male respondents who
were interested in trials belonged in this classification
(details are provided in Table 9). Furthermore, the find-
ings show that the odds ratio of ‘perception of COVID-
19 vaccine trials’ (OR = 1.38) plays a critical role
amongst the respondents along with the perception of
generic vaccines and the COVID-19 vaccine in
particular.
Discussion
This study is the largest and first population-based study
in the UK regarding COVID-19 vaccination and vaccin-
ation trial perceptions. Our results show that less than
half of the respondents (41.4%) are interested in partak-
ing in vaccination trials. Interestingly, the UK COVID-
19 vaccine registry shows that only 357,706 participants
Table 1 Descriptive of survey participants
Respondents Percent
(%)
Interested in COVID-19 vaccine trials
Interested 2020 41.4
Not interested 1346 27.6
Unsure 1518 31.1
Age group






70 and above 552 11.3




Prefer not to say 49 1.0
Qualification
No formal qualifications 127 2.6
Up to A-level 1574 32.2
University degree (under graduation) 1780 36.4
Post-graduation 1010 20.7










White-Gypsy or Irish Traveller 3 0.1
White-Roma 2 0.0
White-others 193 4.0
Asian/Asian British-Indian 258 5.3
Asian/Asian British-Pakistani 30 0.6
Asian/Asian British-Chinese 19 0.4
Asian/Asian British-Bangladeshi 18 0.4




Prefer not to say 49 1.0
Smoker
Smoker 386 7.9




Prefer not to say 3 0.1
Diagnosed health issue
No-health issue 2935 60.1
Health issue 1949 39.9
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have registered as of the 1st December, which is esti-
mated to be only 0.5% of the UK population [13, 14].
Furthermore, only 6 out of 1518 UK COVID-19 studies
were collecting data on ethnicity.
Interestingly, this is the first study to identify that
‘other cities’, smaller cities, such as Leicester and Aber-
deen, are more likely to participate in trials compared to
larger metropolitan ‘core cities’, such as London and
Birmingham. A reason for this could be attributed to
‘core cities’ having greater pockets of inner-city poverty
and health inequalities, compared to ‘outer cities’ [15].
The BAME community are less likely to get involved
in the COVID-19 vaccination trials, despite them being
at higher risk of COVID-19. This correlates with our
study results. The UK COVID-19 vaccine registry also
demonstrates that BAME groups are short of reaching
Table 2 Postcode classification of respondents
Postcode classification Interested (%) Not interested (%) Unsure (%) Total (%)
Core city 304 (15.05) 252 (18.72) 0 (0.00) 556 (11.38)
Other city 698 (34.55) 144 (10.70) 578 (38.08) 1420 (29.07)
Large town 148 (7.33) 9 (0.67) 0 (0.00) 157 (3.21)
Medium town 592 (29.31) 153 (11.37) 34 (2.24) 779 (15.95)
Small town 17 (0.84) 358 (26.60) 701 (46.18) 1076 (22.03)
Village 261 (12.92) 430 (31.95) 205 (13.50) 896 (18.35)
Total respondents 2020 (41.36) 1346 (27.56) 1518 (31.08) 4884 (100)
Table 3 Interested in trials (postcode breakup)
Interested in trials Postcode classifications Total
respondents
Percentage
Core city Other city Large town Medium town Small town Village
Gender (%)
Male 77 203 60 248 6 102 696 34.46
Female 223 494 88 343 11 159 1318 65.25
Prefer not to say 4 1 0 1 0 0 6 0.30
Smoker (%) 17 50 7 62 0 28 164 8.12
Diagnosed health condition (%) 102 300 58 243 9 119 831 41.14
Qualification (%)
No qualification 4 14 3 24 0 9 54 2.67
Non-university goers 79 198 47 241 6 84 655 32.43
Graduates 118 262 53 197 7 102 739 36.58
Post-graduates 89 190 33 94 4 41 451 22.33
Prefer not to say 14 34 12 36 0 25 121 5.99
Age group (%)
Under 18 0 2 0 1 0 1 4 0.20
18–29 28 80 11 30 3 25 177 8.76
30–39 72 89 16 60 2 23 262 12.97
40–49 97 161 35 92 2 49 436 21.58
50–59 57 163 44 151 4 67 486 24.06
60–69 32 137 31 153 4 65 422 20.89
70 + 18 65 11 104 2 31 231 11.44
Prefer not to say 0 1 0 1 0 0 2 0.10
Ethnicity (%)
BAME 43 46 8 13 1 5 116 5.74
Non-BAME 258 650 140 578 16 256 1898 93.96
Prefer not to say 3 2 0 1 0 0 6 0.30
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Table 4 Non-participants in vaccine trials
Vaccine trial
Not sure (1518) Not interested (1346) Total (2864)
Gender (%)
Male 24.51 26.60 25.49
Female 74.70 71.62 73.25
Prefer not to say 0.79 1.78 1.26
Smoker (%) 8.10 7.36 7.75
Diagnosed health condition (%) 41.70 36.03 39.04
Qualification (%)
No qualification 3.10 1.93 2.55
Non-graduates 33.99 29.94 32.09
Graduates 35.57 37.22 36.35
Post-graduates 18.64 20.51 19.52
Prefer not to say 8.70 10.40 9.50
Age group (%)
Under 18 0.07 0.15 0.11
18–29 10.68 14.13 12.30
30–39 13.46 18.37 15.77
40–49 21.02 21.84 21.41
50–59 21.88 21.54 21.72
60–69 20.42 13.91 17.36
70 + 12.47 10.05 11.33
Ethnicity (%)
BAME 7.18 7.28 7.23
Non-BAME 89.00 83.58 86.45
Prefer not to say 3.82 9.14 6.32
Fig. 1 Factors influencing ‘Interest in Vaccine Trials’ (in colour)
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national targets representing less than 8% of the registry
despite representing 13% of the population [13]. Of note,
the Black population only consisted of 0.5% of the total
number. Trials have historically struggled with gaining a
diverse population with greater intervention required to
engage ethnic minority groups into trials [16]. In US
studies, the Black population have been significantly
under-represented in clinical trials [17]. The under-
representation, of the Black community in particular, is
likely to be attributed to mistrust in the medical profes-
sion, as well as historical oppression and health inequal-
ities [18, 19]. A recent study found that only 14% of
Black adults trust that a vaccine would be safe and fewer
than half of the Black adults would accept a licenced
COVID-19 vaccine even if freely available [20].
Our findings suggest that mistrust is a key factor in
non-uptake for vaccination trials. Free text comments
from the survey revolved around the idea of the BAME
community being used as ‘guinea pigs’ for trials to verify
vaccine results, and mistrust around government strat-
egies. Similar sentiments have been found in US studies
[17, 20, 21]. This was likely to have taken influence from
social media views at the time of survey completion, par-
ticularly those highlighting adverse events from vaccine
trials and vaccine trials being rushed. Furthermore, there
are greater anti-vaccination sentiments shared on social
media and are spread quicker compared to positive ones
promoting trial uptake [22]. Multiple studies have
highlighted a number of other reasons as to why trials
tend to disadvantage minorities from attending. This
includes poor health literacy, hidden costs related to
reaching trials, lack of knowledge about the condition
being studied, distrust in the research process and the
researchers, and language barriers [8, 23].
Whilst the highest proportion of BAME respondents
were in cities, there seems to be even less interest from
the BAME community in ‘core cities’ compared to ‘other
cities’. There is a greater proportion of the BAME com-
munity residing in the inner city groups of large cities
and these areas tend to have poorer health outcomes
and suffer greater health inequalities [24, 25], whereas
BAME groups in smaller cities are, however, more likely
to consider partaking in trials as these areas are likely to
be less economically deprived and tend to have more ed-
ucated BAME groups [25].
In our study, the over 70s group was the least willing to
partake in vaccination trials. For the vaccine registry, as of
November 2020, over 80s consist of only 1% of COVID-
19 vaccination trial participants [13]. This is despite pro-
viding much needed diversity and clinical benefit com-
pared to younger and healthier participants. Although the
increased risk of morbidity and poly-pharmacy brings
unique challenges of how effective the vaccine could be,
participation from the elderly can render the trials more
generalisable. Unfortunately, elderly patients tend to have
greater refusal rates than the younger population and
many do not actively seek out clinical trials or are even in-
formed of the availability of clinical trials [8].
There are multiple reasons as to why the elderly hesi-
tate to participate in clinical trials. Many within the
Table 5 Examining the perception of vaccine and its effect on participation in vaccine trials on ethnicity






















Vaccines are safe 3.97 0.938 4.12 0.846 3.96 0.904 (1.784) 0.074* Perception of generic
vaccine on overall health
1.67 0.051 ***
(0.000)
Vaccines keep you healthy 4.07 0.951 4.19 0.931 4.04 0.916 (1.379) 0.168
Vaccines are imp for overall health 4.14 0.963 4.27 0.888 4.14 0.965 (1.43) 0.146
Approved COVID-19 vaccines are safe 4.04 1.019 4.30 0.847 4.03 1.023 (2.803)
0.005***
Perception of COVID-19
vaccine on overall health
1.62 0.044***
(0.000)
Vaccine is a necessity for COVID-19 4.08 1.069 4.24 0.920 4.07 1.035 (1.673) 0.094*
Vaccine is best to prevent COVID-19 4.17 1.058 4.32 0.840 4.16 1.072 (1.983) 0.050**
Only vaccine can control COVID-19 4.11 1.098 4.27 0.926 4.10 1.062 (1.890) 0.061*
COVID-19 vaccine will not harm me 3.94 1.022 4.16 0.854 3.93 1.026 (2.866)
0.005***
Importance of people involved in
vaccine trial




People from all backgrounds are
important to participate in vaccine
trials
4.48 0.982 4.59 0.735 4.58 0.868 (1.530) 0.129
Note: ***Significance is 1% level, **significance at 5% level and *significance at 10% level
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elderly population do not understand the possible bene-
fits of the research being undertaken. Informed consent
in the elderly can also be complicated by the possibility
of cognitive impairment. Transportation difficulties are
consistently cited as a primary concern and a barrier for
elderly adults considering participation in a research
study whilst mobility issues could also potentially make
follow-up visits difficult [8].
In our study, the majority of those over 60s who were
not interested in participating in trials were from ‘small
towns’ and ‘villages’, which are known as more rural
areas. Participation in clinical trials in rural areas is sig-
nificantly lower [26, 27]. Often, these areas have a
greater older population and are further away from trial
sites, making it harder to access. Furthermore, rural par-
ticipants are likely to be less aware about vaccine trials
and have more misperceptions than inner city partici-
pants [21].
The perception of the COVID-19 vaccine can play a
key role in deciding whether an individual will partake
in a vaccine trial. Our results showed that the 40–59 age
group has the greatest interest in participating in vaccin-
ation trials. There is also interest from those who had no
health conditions. These younger and healthier adults
may be motivated by altruism and may see the societal
benefits of vaccine research, surpassing any personal
health risks [28, 29]. Our study found that if one was in-
terested in partaking in the vaccination trial, then they
are also likely to have a positive perception of the
COVID-19 vaccine on overall health and of the vaccine
trials. Furthermore, they are more likely to agree on the
importance of having a variety of people, of all back-
grounds, to participate in vaccine trials.
Despite the majority of our respondents being female,
younger males were more interested in partaking in vac-
cine trials. Historically, women, particularly of child
Table 6 Not interested in trials (postcode breakup)
Not interested in trials Postcode classifications Total
respondents
Percentage
Core city Other city Large town Medium town Small town Village
Gender (%)
Male 56 37 3 37 78 147 358 26.60
Female 193 102 6 112 271 280 964 71.62
Prefer not to say 3 5 0 4 9 3 24 1.78
Smoker (%) 23 12 0 9 24 31 99 7.36
Diagnosed health condition (%) 71 66 3 51 115 179 485 36.03
Qualification (%)
No qualification 3 2 0 1 7 13 26 1.93
Non-university goers 63 38 2 25 117 158 403 29.94
Graduates 93 57 1 77 120 153 501 37.22
Post-graduates 68 28 3 37 74 66 276 20.51
Prefer not to say 25 19 3 13 40 40 140 10.40
Age group (%)
Under 18 0 1 0 1 0 0 2 0.15
18–29 38 14 1 34 58 42 187 13.89
30–39 71 24 2 32 58 56 243 18.05
40–49 70 30 2 41 66 80 289 21.47
50–59 53 29 1 23 88 91 285 21.17
60–69 13 23 2 11 39 96 184 13.67
70 + 5 16 1 7 41 63 133 9.88
Prefer not to say 2 7 0 4 8 2 23 1.71
Ethnicity (%)
AME 78 18 4 33 38 19 190 14.12
Non-BAME 167 122 4 114 314 404 1125 83.58
Prefer not to say 7 4 1 6 6 7 31 2.30
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Table 7 Unsure about trials (postcode breakup)
Unsure (trial participation) Postcode classifications Total
respondents
Percentage
Other city Medium town Small town Village
Gender (%)
Male 193 3 121 55 372 24.51
Female 383 31 571 149 1134 74.70
Prefer not to say 2 0 9 1 12 0.79
Smoker (%) 56 3 49 15 123 8.10
Diagnosed health condition (%) 244 13 263 113 633 41.70
Qualification (%)
No qualification 26 0 15 6 47 3.10
Non-university goers 234 13 184 85 516 33.99
Graduates 183 15 279 63 540 35.57
Post-graduates 80 2 172 29 283 18.64
Prefer not to say 55 4 51 22 132 8.70
Age group (%)
Under 18 0 0 1 0 1 0.07
18–29 51 3 97 10 161 10.61
30–39 47 9 127 20 203 13.37
40–49 86 11 181 39 317 20.88
50–59 128 8 144 50 330 21.74
60–69 154 2 96 56 308 20.29
70 + 111 1 47 29 188 12.38
Prefer not to say 1 0 8 1 10 0.66
Ethnicity (%)
BAME 23 3 118 11 155 10.21
Non-BAME 553 31 575 192 1351 89.00
Prefer not to say 2 0 8 2 12 0.79
Table 8 Examining the perception of vaccine and its effect on participation in vaccine trials











Vaccines are safe 4.260 0.804 3.500 1.097 0.000***
Vaccines keep you healthy 4.323 0.833 3.632 1.121 0.000***
Vaccines are imp for overall health 4.415 0.791 3.648 1.171 0.001***
Approved COVID-19 vaccines are safe 4.400 0.789 3.393 1.214 0.003***
Vaccine is a necessity for COVID-19 4.379 0.868 3.503 1.276 0.000***
Vaccine is best to prevent COVID-19 4.496 0.795 3.522 1.326 0.000***
Only vaccine can control COVID-19 4.428 0.852 3.481 1.349 0.001***
COVID-19 vaccine will not harm me 4.272 0.843 3.356 1.192 0.000***
Importance of people involved in vaccine trial 4.598 0.737 3.873 1.126 0.003***
People from all backgrounds are important to participate in
vaccine trials
4.692 0.698 4.126 1.091 0.001***
Note: ***states significance at 1% level
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bearing age, are harder to recruit for vaccination trials
[30]. Studies have shown that females, particularly those
with underlying health issues, can also have more dis-
trust in pharmaceutical companies and have been previ-
ously under-represented in other respiratory trials [10].
Future challenges
The challenges with recruitment for trials are set to in-
crease, as phase 3 vaccine trials continue to take place
from 2021 [31]. Barriers will become more pronounced
when recruiting to placebo phase 3 trials and further
non-inferiority studies, where vaccines will go head to
head. Thus, there is a need to consider the redesign and
reshaping of these studies to consider these barriers, and
engage the patients in the recruitment plan for these
newly designed studies.
Vulnerable groups, such as the BAME and elderly, are
most likely to receive an approved vaccine first so would
be hesitant to partake in non-approved vaccine trials. It
may also be considered unethical to have these high-risk
groups involved in testing once there is already an ap-
proved vaccine. In terms of the young population, they
may well be one of the last groups to receive an ap-
proved vaccine, and so may be more drawn towards in-
volvement in trials.
The UK will also be the first country to do human
challenge trials with COVID-19 in 2021 [32]. The chal-
lenge trial will involve infecting healthy participants with
the COVID-19 virus in a controlled environment and
then being administered the vaccine [33]. Eligible partic-
ipants must not have any previous health conditions so
that they experience only a mild infection [29, 32]. Con-
sequently, high-risk groups such as the elderly are likely
to be excluded from these trials [29].
Whilst our study shows willingness from those who
have no health conditions, more work still needs to be
done in recruiting high numbers of healthy young par-
ticipants to adequately power these challenge trials. In
our study, the odds ratio for those under 40 was less
than 1, suggesting that there is a large proportion of
young people who are disinterested in participating in
trials. This is somewhat surprising, as previous studies
showed a high willingness (64%) towards vaccination
trials, particularly in university students [28]. More
worrying, any adverse events with these challenge trials
are vulnerable to negatively tipping the balance in vac-
cine uptake rates.
Tackling barriers towards trial recruitment
This study has shown that there is a clear need for
launching national awareness and education campaigns.
The aim would be to improve the public’s knowledge
about the burden of diseases and the need for vaccine
development, thereby harnessing the public’s motivation
to take part [11]. Moreover, campaigns will need to
tackle issues of mistrust whilst remaining cautious with
economic coercion that would aim to drive participation
in the economically marginalised [28].
There may be a need to bring the trial to the subject
where distance is a barrier. Mobile units could be
formed to conduct study visits remotely. This would
eliminate the need for the subject to find transport to
the clinical trial site and reduce travel time, therefore re-
ducing the impact on the subject’s daily commitment
[11]. Alternatively, the use of telemedicine approaches
has become progressively more popular and acceptable
by health authorities, medical doctors and patients after
the current pandemic [34].
Researchers should remain flexible in their approach
and incorporate different types of media and community
resources to enhance recruitment. Community engage-
ment techniques are being increasingly used by the
NIHR, such as the INCLUDE initiative. This initiative
has been formed to ensure there is adequate representa-
tion of under-served groups, which will be done through
careful funding and regulatory approval [35]. Informed
consent for participation in a clinical trial should be kept
simple and short to ensure adequate understanding of
the subject, yet comprehensive to ensure useful informa-
tion can be collected whilst preserving ethical principles
of informed consent [8]. Consent should be made pos-
sible to be done in various languages. Other solutions
can involve having more minority researchers conduct-
ing the trials. Having greater diversity in principal inves-
tigators can be beneficial with this. This may curtail bias
in recruitment of participants from under-represented
Table 9 Examining the perception of vaccine trials vis-à-vis postcode classification (medium town and the rest)
Postcode
classification
Importance of people involved in vaccine trial People from all backgrounds are important
Mean difference Std. error p-value Mean difference Std. error p-value
Core city 0.238* 0.051 0.067 0.134*** 0.048 0.005
Other city 0.037*** 0.041 0.001 0.016*** 0.038 0.000
Large town 0.037* 0.080 0.074 0.041* 0.075 0.085
Small town 0.215*** 0.043 0.000 0.115** 0.041 0.035
Village 0.260*** 0.045 0.000 0.186** 0.042 0.045
Note: ***significant at 1% level and *10% significance level
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populations and allow for improved communication
during recruitment [17, 20, 23].
It is important to engage General Practitioners (GP)
into vaccine trial recruitment, where they can act as key
facilitators for older patients and BAME involvement in
trials [8, 20, 21]. Not only can GPs offer a more persona-
lised approach, but they can also facilitate in building
greater awareness, as often the barrier is a lack of aware-
ness of trials [8]. However, a barrier to this can be a lack
of confidence in GPs being able to recruit trial partici-
pants. This can be overcome by establishing formal
training for GPs on discussing clinical trials with pa-
tients and with specific patient populations to facilitate
improved shared decision-making [17].
Limitations
A limitation of this study is that we were not able to as-
certain the reasons for those not wanting to partake in
vaccination trials. We were only able to deduce their
general perception towards COVID-19 and vaccines, as
well as extracting demographic and geographical data.
Being able to understand the key reasons would be
beneficial in targeting educational campaigns to tackle
specific barriers to trial recruitment.
This is one of the most BAME inclusive COVID-19
vaccination-related studies in the UK. However, our
BAME participant percentage (9.44%) is still below the
overall BAME proportion in the UK, which is approxi-
mately 13% [35]. In particular, we received a very small
amount of Black and East Asian (e.g. Chinese) partici-
pants, so this makes it difficult to deduce the views of
these communities. This reflects the need for further
work to engage the Black and East Asian ethnic groups
into research in general.
Similar to other published surveys, as this was an on-
line survey completed via a computer or smartphone,
there was also selection bias. This would exclude those
with a lack of digital literacy, which could include the
older population and economically marginalised groups,
who are already known to not engage with the UK Na-
tional Health Services digital resources [18]. This survey
is more likely to attract responses from those who have
stronger opinions related to the COVID-19 vaccination
and may be more self motivated to complete this survey.
Conclusion
Our study shows a trial uptake demography that proves
a challenge for future phase 3 trials. The vaccine trials
should represent a diverse participant population in
terms of age, ethnicity and comorbidities. Missing these
targets can lead to reduced validity of the study results
and can often slow down drug development leading to
costly delays. Currently, the UK registry has a very low
trial participant uptake on the elderly and BAME
population — two high-risk priority groups. It is alarm-
ing that these high-risk groups may be losing out on the
opportunity to gain so much from this research, includ-
ing the opportunity to receive lifesaving treatment.
There is a need to design interventional and public
health strategies to engage and encourage trial participa-
tion from specific demographic groups, such as the
BAME community and those aged over 70 population.
Using data from the Office of National Statistics can
help provide a tailored approach [36]. Our data provides
unique insights into participation interest geographically
and can be used to target ongoing and future campaigns
in rural and core inner city populations. Our study pro-
vides possible interventions to increase the uptake for
COVID-19 vaccine trial participations with the overall
goal to acquire a safe and effective vaccine. This can
provide useful in future trials that will continue on for
2021, such as human challenge trials, phase 3 trials and
non-inferiority COVID-19 vaccine studies.
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